CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Bevacizumab and Erlotinibdrug
Likely dose
Bevacizumab and Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00585377
NCT00585377Phase 2Completed
CompareCT.gov

AVF4236s: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

University of Utah·interventional·Posted Jan 3, 2008·Updated Sep 24, 2015

In Brief

A Phase 2 clinical trial evaluating Bevacizumab and Erlotinib for Cancer. Completed, enrolled 50 participants across 1 site.

Detailed Summary

In an attempt to improve the therapeutic index for initial therapy of metastatic NSCLC, the combination of bevacizumab and erlotinib is being proposed as first-line treatment in place of conventional chemotherapy. This trial is intended to provide pilot data for a future randomized trial of this combination of targeted agents versus conventional chemotherapy for advanced NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 3, 2008
Enrollment StartAug 1, 2007
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 18.5 years ago

Interventions

Bevacizumab and Erlotinibdrug

Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days